Perspectives in Personalizing Treatment in ILD

Drs. Martinez and Montesi discuss how to personalize treatment for ILD, particularly IPF. They explain that current personalization is largely driven by side effects, insurance constraints, and patient preferences, emphasizing the need to move toward biomarker- and imaging-guided, pathway-based therapies and innovative clinical trial designs (eg, cohort enrichment and platform trials) similar to oncology.